{{ $ActivityName }}
MBC
MBC-Triple - ve
LABC
Ca Pancreas
NSCLC
Head & Neck
Gastric Cancer
Ovary
Other Indication
1st line therapy
2nd line therapy
Beyond 2nd line therapy
Weekly
3-Weekly
YES
NO
Drug efficacy
Drug safety
Both efficacy and safety
Patient convenience
Prior experience of using BEVETEX in same disease condition
Complete response
Partial response
Stable response
Not assessed
Similar efficacy and similar safety compared to innovator
Similar efficacy and better safety compared to innovator
Better efficacy and safety compared to innovator
Inferior efficacy and safety compared to innovator
Cash
Govt. Reimbursed
Insurance
State Yojna/ Ayushman Bharat Scheme etc